HALO vs. FOLD: Which Stock Is the Better Value Option? [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. Currently, Halozyme Therapeutics has a Zacks Rank of #2 (Buy), while Amicus Therapeutics has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that HALO likely has seen a stronger improvement to its earnings outlook than FOLD has recently. But this is just one factor that value investors are interested in. Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels. Our Value category grades stocks based on a number
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.MarketBeat
- How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? [Yahoo! Finance]Yahoo! Finance
- Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock [Yahoo! Finance]Yahoo! Finance
- Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 10/31/24 - Beat
HALO
Sec Filings
- 12/3/24 - Form 4
- 12/3/24 - Form 4
- 11/12/24 - Form SC
- HALO's page on the SEC website